Goetze, Sandra
van Drogen, Audrey
Albinus, Jonas B.
Fort, Kyle L.
Gandhi, Tejas
Robbiani, Damiano
Laforte, VĂ©ronique
Reiter, Lukas
Levesque, Mitchell P.
Xuan, Yue
Wollscheid, Bernd
Funding for this research was provided by:
Thermo Fisher Scientific (20211215)
Personalized Health and Related Technologies strategic focus area (PHRT), ETHZ (PHRT 2022-601)
Swiss Federal Institute of Technology Zurich
Article History
Received: 31 October 2023
Accepted: 22 March 2024
First Online: 2 April 2024
Declarations
:
: The Ethics Committee of the Kanton Zurich, Switzerland, approved all procedures involving human material, and all patients gave informed consent (K No. 647/800, ID.PB.2018_00194, 2014-0425).
: Not applicable.
: The authors declare the following competing financial interest(s): K.L.F. and Y.X. are employees of Thermo Fisher Scientific, the manufacturer of the Orbitrap Exploris 480 MS instrument used in this research. The intelligent data acquisition hybrid-PRM/DIA MS as a methodology of mass spectrometry is the subject of a patent application filed in 2019 and published in 2021 in multiple countries by Thermo-Fisher Scientific, as CN112798696A; DE102020129645A1; GB2590601A; US2021225627A1. T.G., D.R., V.L., and L.R. are employees of Biognosys, the developer of the software packages SpectroDive and Spectronaut. M.P.L has received unrelated research funding from Oncobit, Roche, Novartis, Molecular Partners, and Scailyte. The remaining authors declare no competing interests.